# Chemoembolization for Hepatocellular Carcinoma

> **NCT02821533** · PHASE2 · TERMINATED · sponsor: **Chinese University of Hong Kong** · enrollment: 24 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **PROCEDURE:** TACE
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT02821533
- **Lead sponsor:** Chinese University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-02
- **Primary completion:** 2017-08
- **Final completion:** 2017-08
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** Poor case accrual
- **Last updated:** 2017-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02821533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02821533, "Chemoembolization for Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02821533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*